Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BOTOX for lateral canthal rhytides (crow's feet) – Phase 3 randomized placebo-controlled trial
2010-020827-28Phase 3Completed
- Sponsor
- Allergan
- Start
- Aug 2010
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in lateral canthal rhytides and wrinkly skin syndrome (WSS) comparing BOTOX with Placebo (2 arms). Primary endpoints: Investigator-assessed crow's feet severity at maximum smile and Subject-assessed crow's feet severity at maximum smile. Started Aug 2010; status: completed.
02
Drugs
botulinum toxin type A
03
Conditions
lateral canthal rhytideswrinkly skin syndrome (WSS)
Beyond the preview
Go deeper on 2010-020827-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-020827-28.